Corbus Pharmaceuticals Holdings, Inc., an emerging drug development company working on the advancement and marketing of its lead product candidate Resunab to address life-threatening and rare fibrotic and inflammatory diseases, announced recently that it will be at the 17th Annual BIO CEO & Investor Conference, presenting its latest research . The conference will be held at the Waldorf Astoria in New York on February 9 and 10, 2015.
Yuval Cohen, Chief Executive Officer of the Corbus Pharmaceuticals, will be presenting an overview of the clinical development projects and plans for Resunab on Monday, February 9 at 11:30 a.m. (Eastern Standard Time).
Resunab is a new synthetic oral drug that displays unique anti-fibrotic and anti-inflammatory activities, and it is being developed to treat both Cystic Fibrosis (CF) and Diffuse Cutaneous Systemic Sclerosis (scleroderma). Pre-clinical and Phase 1 clinical studies demonstrated that Resunab features a very favorable safety profile and offers promising potential in the preclinical models of fibrosis and inflammation. Resunab has the ability to bind itself to the immune cells’ CB2 receptor, and it triggers the inflammatory resolution process that turns the chronic inflammation “off.” The Phase 2 clinical trials are scheduled to begin in 2015.
CF is a genetic disorder that affects the lungs, causing difficulties in breathing and resulting in lung infections. Scleroderma is a systemic autoimmune disease that is characterized by the hardening of the skin and that can also affect internal organs such as the lungs.
A live webcast of the presentation will be available through the company’s website on Corbus Pharmaceutical’s IR Calendar (located in the Investors section). Two hours after the ending of the presentation, the webcast will be available for replay and will remain accessible for about a month.
The Bio CEO & Investor Conference is focused on promoting publicly traded biotechnology companies, and it is the largest independent conference of its type. The conference aims to promote and foster an informative dialogue about the current opportunities to invest between senior biotechnology executives and investors. According to a press release, the 2014 CEO & Investor Conference featured 149 company presentations, 1,820 partnering meetings and registered about 1,400 attendees (half of which were investors).